Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown.
Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
MiyakisSLockshinMDAtsumiTBranchDWBreyRLCerveraR, et al.International consensus statement on an update of the classification criteria for definite APS. J Thromb Haemost2006; 4(2): 295–306.
2.
De CarolisSBottaASantucciSGarofaloSMartinoCPerrilliA, et al.Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol2010; 38: 116–124.
3.
RuffattiATonelloMVisentinMSBontadiAHoxhaADe CarolisS, et al.Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford)2011; 50: 1684–1689.
4.
De CarolisSTabaccoSRizzoFGianniniABottaASalviS, et al.Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. Autoimmun Rev2018; 17(10): 956–966.
5.
De CarolisSMoresiSRizzoFMonteleoneGTabaccoSSalviS, et al.Autoimmunity in obstetrics and autoimmune diseases in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2019; 60: 66–76.
6.
MekinianAAlijotas-ReigJCarratFCostedoat-ChalumeauNRuffattiALazzaroniMG, et al.Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev2017; 16(7): 730–734.
7.
Alijotas-ReigJEsteve-ValverdeEFerrer-OliverasRSáez-CometLLefkouEMekinianA, et al.The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev2019; 18(4): 406–414.
8.
De CarolisSRizzoFTabaccoS. Hydroxychloroquine as additional treatment in pregnant patients with refractory APS. Am J Obstet Gynecol2017; 217(6): 711–712.
9.
BranchDW. Antiphospholipid syndrome and fetal compromise. Thromb Res2004; 114: 415–418.
10.
OgishimaDMatsumotoTNakamuraYYoshidaKKuwabaraY. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies. Pathol Int2000; 50: 224–229.
11.
RandJHWuXXQuinnASChenPPMcCraeKRBovillEG, et al.Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol2003; 163: 1193–2000.
12.
RandJHWuXXQuinnASAshtonAWChenPPHathcockJJ, et al.Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood2010; 115: 2292–2299.
13.
WuXXGullerSRandJH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol2011; 205: 577–514.
14.
De WolfFCarrerasLOMoermanPVermylenJVan AsscheARenaerM. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol1982; 142: 829–834.
15.
ViallCAChamleyLW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev2015; 14: 446–471.
16.
ChamleyLWDuncalfAMMitchellMDJohnsonPM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet1998; 352: 1037–1038.
17.
JovanovićMBozićMKovacevićTRadojcićLPetronijevićMVićovacL. Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo). Acta Histochem2010; 112: 34–41.
HolersVMGirardiGMoLGuthridgeJMMolinaHPierangeliSS, et al.Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med2002; 195: 211–220.
20.
CarbillonLUzanMUzanS. Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet Gynecol Surv2000; 55: 574–581.
21.
CarusoADe CarolisSFerrazzaniSValesiniGCaforioLMancusoS. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol1993; 82: 970–977.
22.
LydenTWVogtENgAKJohnsonPMRoteNS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol1992; 22: 1–14.
23.
SebireNJFoxHBackosMRaiRPatersonCReganL. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod2002; 17: 1067–1071.
24.
MeroniPTedescoFLocatiVecchiADi SimoneNAcaiaB, et al.Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus2010; 19(4): 453–456.
25.
RicklinDHajishengallisGYangKLambrisJD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol2010; 11(9): 785–797.
GirardiGProhaszkaZBullaRTedescoFScherjonS. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol2011; 48(14): 1621–1630.
28.
GirardiGBermanJRedechaPSpruceLThurmanJMKrausD, et al.Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest2003; 112(11): 1644–1654.
29.
PierangeliSSGirardiGVega-OstertagMLiuXEspinolaRGSalmonJ. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum2005; 52(7): 2120–2124.
30.
RegalJFGilbertJSBurwickRM. The complement system and adverse pregnancy outcomes. Mol Immunol2015; 67(1): 56–70.
31.
ZaduraAFMemonAAStojanovichLPerriconeCContiFValesiniG, et al.Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis. J Rheumatol2015; 42(10): 1786–1793.
32.
ShamonkiJMSalmonJEHyjekEBaergenRN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol2007; 196(2): e1–5.
33.
Alijotas-ReigJFerrer-OliverasRRuffattiATincaniALefkouEBerteroMT, et al.The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmun Rev2015; 14(5): 387–395.
34.
RuffattiATonelloMVisentinMSBontadiAHoxhaADe CarolisS, et al.Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: A multicentre, case-control study. Rheumatology2011; 50(9): 1684–1689.
35.
DeguchiMYamadaHSugiura-OgasawaraMMorikawaMFujitaDMikiA, et al.Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome : A multicenter study. J Reprod Immunol2017; 122: 21–27.
36.
TedescoFBorghiMOGerosaMChighizolaCBMacorPLonatiPA, et al.Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol2018; 9: 1388–1388.
37.
MullaMJWeelICPotterJAGyslerSMSalmonJEPeraçoliMTS, et al.Antiphospholipid antibodies inhibit trophoblast toll-like receptor and inflammasome negative regulators. Arthritis Rheumatol2018; 70(6): 891–902.
38.
FishmanPFalach-VakinESredniBMeroniPLTincaniADickerD, et al.Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol1996; 35(2): 80–84.
39.
AbrahamsWMChamleyLWSalmonJE. Emerging treatment models in rheumatology: Antiphospholipid syndrome and pregnancy: Pathogenesis to translation. Arthritis Rheumatol2017; 69(9): 1710–1721.
40.
Alijotas-ReigJEsteve-ValverdeEFerrer-OliverasRLlurbaERuffattiATincaniA, et al.Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Med Clin (Barc)2017; 151(6): 215–222.
41.
IwasawaYKawanaKFujiiTSchustDJNagamatsuTKawanaY, et al.A possible coagulation-independent mechanism for pregnancy loss involving β 2glycoprotein 1-dependent antiphospholipid antibodies and CD1d. Am J Reprod Immunol2012; 67(1): 54–65.
42.
FaulkWPJarretRKeaneMJohnsonPMBackleRJ. Immunological studies of human placentae: complement components in immature and mature chorionic villi. Clin Exp Immunol1980; 40(2): 299–299.
43.
TedescoFNarchiGRadilloOMeriSFerroneSBetterleC. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol1993; 151(3): 1562–1570.
44.
CarboneJOreraMRodríguez-MahouMRodríguez-PérezCSánchez-RamónSSeoaneE, et al.Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus1999; 8(4): 274–278.
45.
De CarolisSBottaASantucciSSalviSMoresiSDi PasquoE, et al.Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus2012; 21(7): 776–778.
46.
ReggiaRZiglioliTAndreoliLBellisaiFIulianoAGerosaM, et al.Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?Rheumatology2012; 51: 2186–2190.
47.
KimMYGuerraMMKaplowitzELaskinCAPetriMBranchDW, et al.Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis2018; 77(4): 549–555.
48.
BertolacciniMLContentoGLennenRSannaGBlowerPJMaMT, et al.Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun2016; 75: 30–38.
